StockData
LBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31

LB PHARMACEUTICALS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$38.81+2.07 (+5.63%)

Close on Oct 19, 2026

Market cap
$1.17B
P/E (TTM)
–
Dividend yield
–

SEC filings

21 of Lb Pharmaceuticals's most recent filings on SEC EDGAR

DocumentFormPeriodFiledSource
Current report8-KSep 15, 2026Sep 15, 2026SEC EDGAR
Current report8-KSep 3, 2026Sep 3, 2026SEC EDGAR
Quarterly report10-QJun 30, 2026Aug 11, 2026SEC EDGAR
Current report8-KAug 11, 2026Aug 11, 2026SEC EDGAR
Current report8-KJul 28, 2026Jul 29, 2026SEC EDGAR
Current report8-KJul 22, 2026Jul 22, 2026SEC EDGAR
Current report8-KJun 8, 2026Jun 10, 2026SEC EDGAR
Current report8-KJun 3, 2026Jun 9, 2026SEC EDGAR
Quarterly report10-QMar 31, 2026May 12, 2026SEC EDGAR
Current report8-KMay 12, 2026May 12, 2026SEC EDGAR
Proxy statementDEF 14AJun 3, 2026Apr 23, 2026SEC EDGAR
Annual report10-KDec 31, 2025Mar 26, 2026SEC EDGAR
Current report8-KMar 26, 2026Mar 26, 2026SEC EDGAR
Current report8-KMar 13, 2026Mar 16, 2026SEC EDGAR
Current report8-KMar 4, 2026Mar 10, 2026SEC EDGAR
Current report8-KFeb 4, 2026Feb 5, 2026SEC EDGAR
Current report8-KNov 10, 2025Nov 13, 2025SEC EDGAR
Current report8-KNov 12, 2025Nov 12, 2025SEC EDGAR
Quarterly report10-QSep 30, 2025Nov 6, 2025SEC EDGAR
Current report8-KNov 6, 2025Nov 6, 2025SEC EDGAR
Current report8-KSep 12, 2025Sep 12, 2025SEC EDGAR